°å¡¡²½¡¡³Ø¡¡¹Ö¡¡ºÂ
¡Ô¸¦µæ³µÍסÕ
£±¡ËÄˤߤÎÅÁ㵡¹½
¡¡ËÜÍèÄˤߤòͶȯ¤·¤Ê¤¤¿¨³Ð»É·ã¤¬¤É¤ÎÍͤʿÀ·Ð²óÏ©¤äÀ¸Âΰø»Ò¤ò²ð¤·¤ÆÄˤߡʥ¢¥í¥Ç¥£¥Ë¥¢¡Ë¤òͶȯ¤¹¤ë¤Î¤«¡¢Ä˳вáÉÒÈ¿±þ¤ËÈæ¤·¤Æ¡¢¤½¤Îȯ¸½µ¡½ø¤Ï̤¤À¤ËÉÔÌÀ¤ÊÅÀ¤¬Â¿¤¤¡£Ä˳ФÎÅÁ㤬°ì¼¡µá¿´ÀÀþ°Ý¤ÎÆþÎÏ¡¢ÀÔ¿ñ¸å³Ñ¤Î¿À·ÐºÙ˦¡¢Áع½Â¤¤Ç¤É¤Î¤è¤¦¤ËÀ©¸æ¤µ¤ì¤Æ¤¤¤ë¤Î¤«¡¢¤Ê¤¼¿¨³Ð¤¬Ä˳ФȤ·¤Æ¸íǧ¤µ¤ì¤ë¤Î¤«¤È¤¤¤¦½ÅÍפ«¤Ä´ðËÜŪ¤ÊÌäÂê¤ò¿À·Ð¤Î²ÄÁºÀ¤Ë¾ÇÅÀ¤ò¤¢¤Æ¤Æ¸¦µæ¤ò¿Ê¤á¤Æ¤¤¤ë¡£Åö¶µ¼¼¤Ë¤ª¤¤¤Æ¥Î¥Ã¥¯¥¢¥¦¥È(KO)¥Þ¥¦¥¹¤òÍѤ¤¤¿¹ÔưÌôÍý¼Â¸³¤«¤é¡¢¥×¥í¥¹¥¿¥°¥é¥ó¥¸¥ó (PG) ¡¢¥ª¥Ô¥ª¥¤¥É¡Ê¥Î¥·¥»¥×¥Á¥ó¡ÊNoc/OFQ¡Ë¡¢¥Î¥·¥¹¥¿¥Á¥ó¡ÊNST¡Ë¡Ë¡¢¥°¥ë¥¿¥ß¥ó»À¤ä°ì»À²½ÃâÁÇ (NO) ¤¬¥¢¥í¥Ç¥£¥Ë¥¢¤Ë´ØÍ¿¤¹¤ë¤³¤È¤òÌÀ¤é¤«¤Ë¤·¤Æ¤¤¿¡£º£Ç¯Å٤ϡ¢¥¢¥í¥Ç¥£¥Ë¥¢¤Ë´ØÍ¿¤¹¤ë¿·µ¬°äÅÁ»Ò¤Î¥¯¥í¡¼¥Ë¥ó¥°¡¢°äÅÁ»Ò¤Îȯ¸½ÊѲ½¤Ëȼ¤¦ÄˤߤÎȯÀ¸µ¡¹½¡¢ÀÔ¿ñ¥¹¥é¥¤¥¹¤òÍѤ¤¤¿¿À·Ð²óÏ©Ì֤ζõ´ÖŪ¡¢»þ´ÖŪ¥¤¥á¡¼¥¸¥ó¥°¡¢È¯¸÷ÃÁÇò¼Á´Ö¤Ç¥¨¥Í¥ë¥®¡¼°Üư¡ÊBRET¡¢Bioluminescence Resonance Energy Transfer )¤òÍøÍѤ·¤¿Noc/OFQ¤ÈNST¤Î»ºÀ¸Ä´Àᵡ¹½¤Ë´Ø¤¹¤ë¸¦µæ¤ò¹Ô¤Ã¤¿¡£
i)¡¡¥¢¥í¥Ç¥£¥Ë¥¢¤Ë´ØÍ¿¤¹¤ëÆÃ°ÛŪ°äÅÁ»Ò¤ÎñΥ
¡¡²æ¡¹¤ÏPGF2¦Á¤Ë¤è¤ë¥¢¥í¥Ç¥£¥Ë¥¢¤¬¥«¥×¥µ¥¤¥·¥óÈó´¶¼õÀ¤ÎA¦ÂÀþ°Ý¤ò²ð¤¹¤ë¤Î¤ËÂФ·¡¢PGE2¤Ë¤è¤ë¥¢¥í¥Ç¥£¥Ë¥¢¤Ï¥«¥×¥µ¥¤¥·¥ó´¶¼õÀ¤ÎCÀþ°Ý¤ò²ð¤¹¤ë¤³¤È¤«¤é¡¢¥¢¥í¥Ç¥£¥Ë¥¢¤Î£²¤Ä¤Î°Û¤Ê¤ëÈ¿±þ·ÐÏ©¡¢È¯¾Éµ¡¹½¤¬¤¢¤ë¤³¤È¤òÌÀ¤é¤«¤Ë¤·¤¿¡£
PGF2¦Á¤Ë¤è¤ë¥¢¥í¥Ç¥£¥Ë¥¢¤Ï¥â¥ë¥Ò¥Í¤ÎÄÃÄ˸ú²Ì¤¬¤ß¤é¤ì¤Ê¤¤¤³¤È¤«¤é¡¢¤³¤Îȯ¾Éµ¡¹½¤òÌÀ¤é¤«¤Ë¤¹¤ë¤³¤È¤ÏÈó¾ï¤Ë½ÅÍפǤ¢¤ë¡£PGF2¦Á¤Ë¤è¤ë¥¢¥í¥Ç¥£¥Ë¥¢¤òÆÃ°ÛŪ¤Ë¾Ã¼º¤µ¤»¤ë½èÃÖÊýË¡¤ò¸«¤¤¤À¤·¡¢½èÃÖ·²¤È̤½èÃÖ·²¤ÎÀÔ¿ñ¤«¤éÄ´À½¤·¤¿cDNA´Ö¤Î¥µ¥Ö¥È¥é¥¯¥·¥ç¥ó¤Ë¤è¤ê15¼ïÎà¤Î´ûÃΤΰäÅÁ»Ò¤È14¼ïÎà¤Î̤ÃΤΰäÅÁ»Ò¤òƱÄꤷ¤¿¡£¸Ä¡¹¤Î°äÅÁ»Ò¤Î±ö´ðÇÛÎóÁ´Ä¹¤ÎñΥ¤ÈÀÔ¿ñ¤Ç¤Î¡¡mRNA¤Îȯ¸½¤Î³Îǧ¤ò¹Ô¤Ã¤¿¡£¤³¤ì¤é°äÅÁ»Ò¤Î¥¢¥ó¥Á¥»¥ó¥¹¥ª¥ê¥´¤ò¹çÀ®¤·¤ÆÎ±ÃÖ¥«¥Æ¡¼¥Æ¥ë¤Ç1½µ´Ö¤ËÅϤêÀÔ¿ñ¤ËÅêÍ¿¤·¤¿¡£¤¤¤¯¤Ä¤«¤Î¥¢¥ó¥Á¥»¥ó¥¹¥ª¥ê¥´¤ÏPGF2¦Á¤Ë¤è¤ë¥¢¥í¥Ç¥£¥Ë¥¢¤òÍÞÀ©¤·¤¿¡£¤³¤ì¤é¤Î°äÅÁ»Ò¤Îµ¡Ç½²òÀϤò¤µ¤é¤Ë¿Ê¤á¤Æ¤¤¤ë¡£
ii)¡¡¿À·Ð¥Ú¥×¥Á¥ÉNoc/OFQ¤ÈNST¤Ë¤è¤ëÄ˳ÐÀ©¸æ¤Îʬ»Ò¥á¥«¥Ë¥º¥à
Noc/OFQ¤ÎÁ°¶îÂÎÃÁÇò¾å¤Ë¡¢Noc/OFQ¤Ë¤è¤ëÄ˳ÐÈ¿±þ¤òÍÞÀ©¤¹¤ëÀ¸Íý³èÀ¥Ú¥×¥Á¥É¤òȯ¸«¤·¡¢¥Î¥·¥¹¥¿¥Á¥ó
(NST)¤È̾¤Å¤±¤¿¡£NST¤ÈNoc/OFQ¤Ï¡¢ÀÔ¿ñ¸å³Ñ¤Ë¤ª¤¤¤Æ¤Ï¤È¤â¤ËɽÁؤ˸ºß¤·¡¢³Æ¡¹¤Î¼õÍÆÂΤò²ð¤·¤Æ¤½¤ÎºîÍѤòȯ´ø¤¹¤ë¤³¤È¤òÌÀ¤é¤«¤Ë¤·¤Æ¤¤¿¡£NST¤ÈNoc/OFQ¤Ë¤è¤ëÄ˳ÐÀ©¸æµ¡¹½¤òÌÀ¤é¤«¤Ë¤¹¤ë¤¿¤á¡¢NST¼õÍÆÂΤÎñΥƱÄê¤È¥Ú¥×¥Á¥É¤Î»ºÀ¸Í·Î¥µ¡¹½¤Î²òÌÀ¤ò¼´¤Ë¸¦µæ¤ò¿Ê¤á¤¿¡£
a)¡¡NST¼õÍÆÂÎ¤ÎÆ±Äê
¡¡125Iɸ¼±NSTͶƳÂΤò¹çÀ®¤·¡¢¥Þ¥¦¥¹ÀÔ¿ñËì²èʬ¤Ç¥Õ¥©¥È¥¢¥Õ¥£¥Ë¥Æ¥£¥é¥Ù¥ê¥ó¥°¤ò¹Ô¤Ã¤¿·ë²Ì¡¢Ìó33
kDa¤Î·ë¹çÃÁÇò¤¬ÆÃ°ÛŪ¤Ëɸ¼±¤µ¤ì¤¿¡£¤³¤ÎÃÁÇò¤Ï¡¢ºÙ˦Ëì¤Î¥é¥Õ¥È²èʬ¤Ë¸ºß¤·¡¢GTP¦ÃS¤Î½èÍý¤Ë¤è¤ê¾Ã¼º¤·¤¿¤³¤È¤«¤é¡¢GTP·ë¹çËìÃÁÇò¤Î²ÄǽÀ¤¬¼¨º¶¤µ¤ì¤¿¡£¸½ºß¡¢¤³¤ÎÃÁÇò¤ÎÀºÀ½¡¢Æ±ÄêµÚ¤Ó°äÅÁ»Ò¤Î¥¯¥í¡¼¥Ë¥ó¥°¤ò»î¤ß¤Æ¤¤¤ë¡£
b)¡¡¥Ú¥×¥Á¥É¤Î»ºÀ¸Í·Î¥µ¡¹½
¡¡¥Ú¥×¥Á¥É¤Î»ºÀ¸¡¢Í·Î¥µ¡¹½¤ª¤è¤Ó¡¢»ºÀ¸Ä´Àá¤òô¤¦¤È¹Í¤¨¤é¤ì¤ë¥Ú¥×¥Á¥É¤Î¥×¥í¥»¥Ã¥·¥ó¥°¤Ë´ØÍ¿¤¹¤ëÃÁÇòʬ²ò¹ÚÁǤβòÌÀ¤òÌÜŪ¤È¤·¡¢À¸ÊªÈ¯¸÷ÃÁÇò¤ÎƳÆþ¤µ¤é¤Ë¡¢¤½¤ÎÃÁÇò´Ö¤Î¥¨¥Í¥ë¥®¡¼°Üư¤ò±þÍѤ·¤¿ÊýË¡(BRET)¤Î³ÎΩ¤ò»î¤ß¤¿¡£(ȯ¸÷¹ÚÁÇ)−(NST¡¦Noc/OFQ)−(GFP)¤ÎÍ»¹çÃÁÇò¤Î°äÅÁ»Ò¥Ù¥¯¥¿¡¼¤ò¹½ÃÛ¤·¡¢ºÙ˦¤ËƳÆþ¤·¤¿¡£¤³¤ÎÍ»¹çÃÁÇò¤Ï¡¢NST¡¦Noc/OFQ¥Ú¥×¥Á¥É¤¬¥×¥í¥»¥Ã¥·¥ó¥°¤µ¤ì¤Ê¤¤¾ì¹ç¤Ïȯ¸÷¹ÚÁǤθ÷¤Ï¥¨¥Í¥ë¥®¡¼°Üư¤Ë¤è¤ê¡¢GFP¤òÎ嵯¤·Î理Îȯ¸÷¤È¤Ê¤ë¤³¤È¤ò¡¢NST¡¦Noc/OFQ¥Ú¥×¥Á¥É¤¬¥×¥í¥»¥Ã¥·¥ó¥°¤µ¤ì¤¿¾ì¹ç¤Ï¡¢È¯¸÷¹ÚÁǼ«ÂΤÎÀÄ¿§¸÷¤òȯ¤¹¤ë¤³¤È¤òǧ¤á¤¿¤³¤È¤è¤ê¡¢¥Ú¥×¥Á¥É¤Î¥×¥í¥»¥Ã¥·¥ó¥°¤ò¥â¥Ë¥¿¡¼¤Ç¤¤ë¥×¥í¡¼¥Ö¤¬³ÎΩ¤Ç¤¤¿¡£¤µ¤é¤Ë¡¢È¯¿§¸÷¤ò»ØÉ¸¤Ë¥Ú¥×¥Á¥É¤Îʬ²ò²áÄø¤òÄÉÀפ·¡¢¥×¥í¥»¥Ã¥·¥ó¥°¹ÚÁǤΥ¯¥í¡¼¥Ë¥ó¥°¡¢Èù¼åȯ¸÷²òÀϸ²Èù¶ÀÁõÃ֤ˤè¤êȯ¸÷¤òÄÉÀס¢¥×¥í¥»¥Ã¥·¥ó¥°²áÄø¤Î¥ê¥¢¥ë¥¿¥¤¥à²òÀϤò»î¤ß¤Æ¤¤¤ë¡£
iii)¡¡¿¯³²À»É·ã¤Ë¤è¤ë°äÅÁ»Òȯ¸½Í¶Æ³¤ÈÄ˳вáÉÒÈ¿±þ
¡¡PGI2¡Ê¥×¥í¥¹¥¿¥µ¥¤¥¯¥ê¥ó¡Ë¼õÍÆÂΡÊIP¡ËKO¥Þ¥¦¥¹¤Ç¤Ï¥«¥é¥²¥Ë¥ó¤Ë¤è¤ë±ê¾ÉÈ¿±þ¤ä¿Ý»À¥é¥¤¥¸¥ó¥°»î¸³¤ÇÄË³Ð¹ÔÆ°¤¬ÍÞÀ©¤µ¤ì¤ë¤Î¤ËÂФ·¡¢¥Û¥Ã¥È¥×¥ì¡¼¥È»î¸³¤ätail-flick»î¸³¤ÇÇ®»É·ã¤ËÂФ¹¤ëÈ¿±þ¤ËÊѲ½¤¬¤Ê¤«¤Ã¤¿¤³¤È¤«¤é¡¢PGI2¤ÏËö¾¿¤ÇÄ˳ÐÈ¿±þ¤Ë´ØÍ¿¤¹¤ë¤³¤È¤¬¼¨º¶¤µ¤ì¤Æ¤¤¤¿¡£Âí¨¤Ë¥«¥é¥²¥Ë¥ó¤òÃí¼Í¤·¤Æ£±»þ´Ö¤«¤éCOX-2¤Î£íRNA¤È¤È¤â¤Ë¡¢IP¼õÍÆÂΣíRNA¤Îȯ¸½¤¬Áý²Ã¤·¤¿¡££¶»þ´Ö¸å¤ËIP¼õÍÆÂÎºîÆ°Ìô¤ò¿ñ¹ÐÆâ¤ËÃíÆþ¤¹¤ë¤È½èÃÖ¦¡¢Ì¤½èÃÖ¦¤È¤â¤ËÄ˳вáÉÒÈ¿±þ¤¬À¸¤¸¤¿¡£Ëö¾¿Éô°Ì¤Î±ê¾É¤Ëȼ¤Ã¤Æ¡¢¤³¤ì¤Þ¤Çȯ¸½¤·¤Æ¤¤¤Ê¤«¤Ã¤¿IP¼õÍÆÂΤ¬Í¶Æ³¤µ¤ì¡¢»ºÀ¸¤¬Áý²Ã¤·¤¿PGI2¤¬IP¼õÍÆÂΤò³èÀ²½¤·¤ÆÃæ¿õÀ¤ËÄ˳ÐÅÁã¤Ë´ØÍ¿¤¹¤ë·ë²Ì¤Ï¡¢¿¯³²À»É·ã¤Î»ý³¤Ë¤è¤êͶƳ¤µ¤ì¤ëÀ¸Âΰø»Ò¤Î´ØÍ¿¤ÏKO¥Þ¥¦¥¹¤Ç¤Ï¸«Íî¤È¤µ¤ì¤ë²ÄǽÀ¤ò¼¨º¶¤¹¤ë¤â¤Î¤Ç¤¢¤ë¡£
iv)¡¡¥¢¥í¥Ç¥£¥Ë¥¢¤Ë´Ø¤¹¤ë¿À·Ð²óÏ©Ì֤ζõ´ÖŪ¤ª¤è¤Ó»þ´ÖŪ¥¤¥á¡¼¥¸¥ó¥°
¡¡
ÄË¤ß¤ÎÆ°Êª¥â¥Ç¥ë¤è¤êÆÀ¤¿¥¢¥í¥Ç¥£¥Ë¥¢¤Î¹ÔưÌôÍý³ØÅª·ë²Ì¤ò´ð¤Ë¡¢¥Ó¥Ç¥ª¥Þ¥¤¥¯¥í¥¹¥³¥Ô¡¼¤Ë¤è¤ë¥¤¥á¡¼¥¸¥ó¥°Ë¡¤òÍѤ¤¤Æ¥¢¥í¥Ç¥£¥Ë¥¢Í¶Æ³¤Ë´ØÍ¿¤¹¤ë¿À·Ð²óÏ©¤ÎÆó¼¡¸µÅª²Ä»ë²½¤ò»î¤ß¤Æ¤¤¤ë¡£¤½¤Î²óÏ©¤Ë¤ª¤±¤ëPG¤äÄ˳Ф˴ØÏ¢¤¹¤ë¿À·Ð¥Ú¥×¥Á¥ÉÎà¤ÎºîÍѵ¡¹½¤Î¥¤¥á¡¼¥¸¥ó¥°¤ò¸÷³ØÅªËìÅŰ̡¢ºÙ˦Æâ¥«¥ë¥·¥¦¥à¥¤¥ª¥óÇ»ÅÙ¡Ê[Ca2+]i¡Ë¡¢NO¤Ë¤Ä¤¤¤ÆÃ±ÆÈ¤¢¤ë¤¤¤ÏƱ»þ¤ËÆó½ÅÀ÷¿§¤·¤Æ¿ë¹Ô¤·¡¢¹ÔưÌôÍý³ØÅª·ë²Ì¤ÈÈæ³Ó¸¡Æ¤¤·¤Æ¤¤¤ë¡£Îã¤òµó¤²¤ë¤È¡¢PGF¼õÍÆÂÎ
(FP) KO¥Þ¥¦¥¹¤ÎÀÔ¿ñ¥¹¥é¥¤¥¹É¸Ëܤˤª¤±¤ë[Ca2+] i ưÂÖ¤ò¥¤¥á¡¼¥¸¤·¤¿¤È¤³¤í¡¢ÀÔ¿ñ¸å³Ñ¤ÎIVÁØÉí¶á¤Ç¡¢¥ª¥Ô¥ª¥¤¥É¼õÍÆÂΤγƼ異¥´¥Ë¥¹¥ÈU50488H
(¦Ê¼õÍÆÂÎ)¡¢DPDPE¡Ê¦Ä¼õÍÆÂΡˡ¢DAMGO¡Ê¦Ì¼õÍÆÂΡˤ¬[Ca2+] i ¾å¾º¤ò°ú¤µ¯¤³¤·¡¢U50488H¤¬ºÇ¤âÂ礤Ê[Ca2+] i
¾å¾º¤ò°ú¤µ¯¤³¤¹¤³¤È¤ò¸«¤¤¤À¤·¤¿¡£L5·ëå§¥â¥Ç¥ë¤ÇÄ˳вáÉÒÈ¿±þ¤ò°ú¤µ¯¤³¤¹¸ÄÂΤòÍѤ¤¤ÆÀÔ¿ñ¤Ë¤ª¤±¤ëNO»ºÀ¸¤òNO¥×¥í¡¼¥Ö»îÌô¤ÎDAF-FM¤òÍѤ¤¤Æ¥¤¥á¡¼¥¸¥ó¥°¤·¤¿¤È¤³¤í¡¢·ë姤·¤¿Â¦¤ÎNO¾å¾º¤¬È¿ÂΦ¤è¤ê¤âÂ礤¤·¹¸þ¤Ë¤¢¤ë¤³¤È¤ò´Ñ»¡¤·¤¿¡£¥°¥ë¥¿¥ß¥ó»ÀͶƳÂΤǤÏ[Ca2+]
i ưÂÖ¤ÈNOưÂ֤˲òÎ¥¤¬¸«¤¤¤À¤µ¤ì¤¿¡£¤³¤Î¤è¤¦¤Ë¡¢ÀÔ¿ñ¥¹¥é¥¤¥¹¤òÍѤ¤¤ë¥¤¥á¡¼¥¸¥ó¥°¼Â¸³¤Ï¡¢Ä˳ФοÀ·Ð²óÏ©ÌÖ¤ò²òÀϤ¹¤ë¼êÃʤȤ·¤Æ´üÂÔ¤µ¤ì¤ë¡£
£²¡Ë´Îµ¡Ç½Ä´Àá°ø»Ò¤È¤·¤Æ¤Î¥µ¥¤¥È¥«¥¤¥ó¤ÎÌò³ä
¡¡ÉÂÂÖ»þ¤Î´Î¡¤Ç¤Ï¡¢±ê¾ÉÀ¥µ¥¤¥È¥«¥¤¥ó¤Ë¤è¤ëÍÍ¡¹¤Ê°äÅÁ»Ò¤Îȯ¸½Í¶Æ³¤¬¤½¤Îµ¡Ç½ÉÔÁ´¤È¿¼¤¯´ØÏ¢¤·¤Æ¤¤¤ë¡£¥¤¥ó¥¿¡¼¥í¥¤¥¥ó1¦Â (IL-1¦Â)
¤Ê¤É¤Ë¤è¤êͶƳ¤µ¤ì¤ëͶƳ·¿°ì»À²½ÃâÁǹçÀ®¹ÚÁÇ¡ÊiNOS¡Ë¤Ï¿Î̤ÎNO¤ò»ºÀ¸¤¹¤ë¡£NO¤Ï´Î¾ã³²¤½¤Î¤â¤Î¤ò°ú¤µ¯¤³¤·¤µ¤é¤Ë°²½¤µ¤»¤ëºîÍѤȵդˤ½¤Î¾ã³²¤ò¸º¼å²½¤¹¤ëÁêÈ¿¤¹¤ë£²¤Ä¤ÎºîÍѤò¤â¤Ä¡£¤·¤«¤·¤Ê¤¬¤éž¼Ì°ø»ÒNF-¦ÊB¤ò²ð¤·¤¿iNOSͶƳ¤ÎÀ©¸æ¥á¥«¥Ë¥º¥à¤Î¾ÜºÙ¤ÏÉÔÌÀ¤ÊÅÀ¤¬Â¿¤¤¡£º£Ç¯ÅÙ¤ÏÆ°Êª¥â¥Ç¥ë¡¢½éÂåÇÝÍܴκÙ˦¤È¾®Ä²³ôºÙ˦¤òÍѤ¤¤Æ¡¢iNOS/NOͶƳ¤ÎºîÍѵ¡¹½¤òÌÀ¤é¤«¤Ë¤·¤¿¡£
i)¡¡´ÎÅüÂå¼Õ¤ÈNO»ºÀ¸Í¶Æ³¤È¤Î´Ø·¸
´Î´â¤Ê¤É¤Î¼ê½Ñ¤Ë¤ª¤¤¤Æ¡¢´ÎÉôʬÀÚ½ü¸å¤Î´¶À÷¡¢±ê¾É¤Ë¤è¤ê´Îµ¡Ç½ÉÔÁ´¤¬µ¯¤³¤ë¡£NO¤Ï´Îµ¡Ç½Äã²¼¤Ë´ØÍ¿¤·¤Æ¤¤¤ë¤ÈÊó¹ð¤µ¤ì¤Æ¤¤¤ë¤¬ÉÔÌÀ¤ÊÅÀ¤¬Â¿¤¤¡£NO
¤Ë¤ÏiNOS°Ê³°¤Ë¹½À®·¿NOS
(cNOS)¤¬¤¢¤ê¡¢ÁªÂòŪNOSÁ˳²Ìô¤¬¤Ê¤¤¸½¾õ¤Ç¤Ï¡¢´Îµ¡Ç½¤Ë¤É¤ÎNOS¤¬´ØÍ¿¤¹¤ë¤Î¤«·ëÏÀ¤Å¤±¤ë¤³¤È¤ÏÆñ¤·¤¤¡£º£Ç¯ÅÙ¡¢ÌîÀ·¿¥Þ¥¦¥¹¤ÈiNOS-KO ¥Þ¥¦¥¹¤«¤é½éÂåÇÝÍܴκÙ˦¤òÄ´À½¤·¡¢LPS¤ÈIL-1¦Â¡¢TNF¦Á¡¢INF¦Ã¤Î¥µ¥¤¥È¥«¥¤¥óº®¹ç±Õ (CM)
¤ÇͶƳ¤µ¤ì¤ëiNOSͶƳ¤È¥¨¥Í¥ë¥®¡¼Âå¼Õ¤È¤Î´Ø·¸¤ò¸¡Æ¤¤·¤¿¡£iNOS¤Ë¤è¤ê»ºÀ¸¤µ¤ì¤ë
NO¤Ï´ÎºÙ˦¤ÎATP¥ì¥Ù¥ë¤ä¥±¥È¥óÂÐÈæ¤Ê¤É¥¨¥Í¥ë¥®¡¼Âå¼Õ¤Ë´ØÍ¿¤¹¤ë¤¬¡¢¥¤¥ó¥¹¥ê¥ó¤Ë¤è¤ë¥°¥ê¥³¡¼¥²¥ó¹çÀ®¤Ë¤Ï´ØÍ¿¤·¤Ê¤¤¤È¤¤¤¦ÌÀ²ò¤Ê·ëÏÀ¤¬ÆÀ¤é¤ì¤¿¡£¤³¤Î·ë²Ì¤Ï¡¢´ÎÉôʬÀÚ½ü¥é¥Ã¥È¥â¥Ç¥ë¤Î·ë²Ì¤È¤â°ìÃפ·¡¢ATP¥ì¥Ù¥ë¤Î¸º¾¯¤ÏNOÁý²Ã¤Ë¤è¤ë¥ß¥È¥³¥ó¥É¥ê¥¢µ¡Ç½ÉÔÁ´¤ËͳÍ褹¤ë¤È¹Í¤¨¤é¤ì¤ë¡£¤³¤ì¤é¤Î·ë²Ì¤Ï¡¢iNOS¤Ë¤è¤ëNO»ºÀ¸¤ÎÂ¥¿Ê¤òÍÞÀ©¤¹¤ë¤³¤È¤¬´Îµ¡Ç½Äã²¼¤ÎËɻߤËÂ礤¯¹×¸¥¤¹¤ë¤³¤È¤ò¼¨º¶¤·¤Æ¤¤¤ë¡£
ii)¡¡¾®Ä²³ôºÙ˦¤Ë¤ª¤±¤ëiNOS¤ÎͶƳ
¡¡¤³¤ì¤Þ¤Ç¡¢EGF¤¬¾®Ä²°Ü¿¢¤Îµ¡Ç½²óÉü¤òÂ¥¿Ê¤¹¤ë¤³¤È¤òÊó¹ð¤·¤Æ¤¤¿¤¬¡¢EGF¤ÎºîÍѵ¡½ø¤òÌÀ¤é¤«¤Ë¤¹¤ë¤¿¤á¤Ë¡¢¾®Ä²³ôºÙ˦¤Ç¤ÎiNOSͶƳ¤ËµÚ¤Ü¤¹¸ú²Ì¤ò¸¡Æ¤¤·¤¿¡£½éÂåÇÝÍܴκÙ˦¤È°Û¤Ê¤ê¡¢¾®Ä²³ôºÙ˦¤Ç¤Ï¡¢IL-1¦Â¤ÇiNOS¤ÎͶƳ¤Ïµ¯¤³¤é¤º¡¢EGF¤òź²Ã¤¹¤ë¤³¤È¤Ç¤Ï¤¸¤á¤ÆiNOS¤¬Í¶Æ³¤µ¤ì¡¢·ÑÂå¤ò³¤±¤ë¤³¤È¤Ë¤è¤ê¡¢EGF¤Î´óÍ¿¤¬Äã²¼¤¹¤ë¤È¤¤¤¦¶½Ì£¿¼¤¤¼Â¸³·ë²Ì¤¬ÆÀ¤é¤ì¤¿¡£¡¡
£³¡Ë¡¡À¸¿£´ï·Ï¤Ë¤ª¤±¤ë movo°äÅÁ»Ò¤ÎKO¥Þ¥¦¥¹¤ÎºîÀ½
¡¡Ó®Æýưʪ¤Ë¤ª¤±¤ëÀ¸¿£ºÙ˦¤Îʬ²½µ¡¹½¤Îʬ»Ò¥ì¥Ù¥ë¤Ç¤Î²òÀϤòÌÜŪ¤È¤·¤Æ¡¢¥·¥ç¥¦¥¸¥ç¥¦¥Ð¥¨¤ÇÍñÁã¤Îʬ²½¤ª¤è¤ÓÍñ·ÁÀ®¤Ë´Ø¤ï¤ëovo°äÅÁ»Ò¤Î¥Þ¥¦¥¹¥Û¥â¥í¥°¤Î¥¯¥í¡¼¥Ë¥ó¥°¤ò»î¤ß¡¢¥Þ¥¦¥¹ÁêÆ±°äÅÁ»Ò¤Ç¤¢¤ëmovo°äÅÁ»Ò¤ÎñΥ¤ËÀ®¸ù¤·¤¿¡£¹½Â¤²òÀϤηë²Ì¡¢movo¤Îž¼Ì»ºÊª¤¬Zn¥Õ¥£¥ó¥¬¡¼DNA·ë¹ç¥â¥Á¡¼¥Õ¤òͤ¹¤ë³Ë¥¿¥ó¥Ñ¥¯¤Ç¤¢¤ë¤³¤È¡¢µÚ¤Ó¤½¤ÎmRNA¤Ï¥Þ¥¦¥¹¤Ç¤ÏÀ¸¸å£³½µÎð°Ê¹ß¤ÎÀºÁã¤ÇÆÃ°ÛŪ¤Ëȯ¸½¤·¤Æ¤¤¤ë¤³¤È¤òÌÀ¤é¤«¤Ë¤·¤¿¡£¤½¤Î¸å¤Î²òÀϤˤè¤Ã¤Æ¡¢mOVOÃÁÇò¤¬¼ÂºÝ¤ËDNA¤ÎÆÃÄê¤Î±ö´ðÇÛÎó¤Ë·ë¹ç¤·¤Æ¤ª¤ê¡¢Å¾¼ÌÀ©¸æÎΰè¤Ë¤½¤ÎÇÛÎó¤ò´Þ¤à°äÅÁ»Ò¤Îž¼Ì³èÀ¤òin vitro¤ÎÇÝÍܷϤÇÊÑÆ°¤µ¤»¤ë¤³¤È¡¢ÍñÁã·ÁÀ®ÉÔǽ¤Îovo-/-¥·¥ç¥¦¥¸¥ç¥¦¥Ð¥¨¤Ëmovo¤òÌ᤹¤ÈÉôʬŪ¤ËÍñ·ÁÀ®¤¬¤ß¤é¤ì¤ë¤³¤È¤òÌÀ¤é¤«¤Ë¤·¤¿¡£movo°äÅÁ»Ò¤ÎKO¥Þ¥¦¥¹¤Ïlethal¤ÇÂÛÈ×·ÁÀ®¤Ë°Û¾ï¤¬Ç§¤á¤é¤ì¤¿¡£Å¾¼Ì°ø»Ò¤È¤·¤Æmovo¤¬¤É¤Î¤è¤¦¤Ë´ØÍ¿¤¹¤ë¤Î¤«¡¢¤µ¤é¤Ëconditional KO¥Þ¥¦¥¹¤ÎºîÀ½¤ò¹Ô¤¤¡¢mOVOÃÁÇò¤¬¤É¤Î¤è¤¦¤ËÀº»Ò·ÁÀ®¤Ë´ØÍ¿¤¹¤ë¤Î¤«²òÌÀ¤ò¿Ê¤á¤Æ¤¤¤ë¡£
¡Ô¸¦µæ¶ÈÀÓ¡Õ
³Ø²ñ»ïÅù
- Yasuda K, Okumura T, Okada H, Nakajima T, Aoki J, Arai H, Inoue K, Nishizawa M, Ito S and Kanzaki H(2001)
Platelet-activating factor acetylhydrolase isoformsµand ¶in human uterus.
comparisons with pregnant uterus and myoma.
Biol Reprod 64:339-344
- Kaibori M, Inoue T, Tu W, Oda M, Kwon A-H, Kamiyama Y and Okumura T(2001)
FK506, but not cyclosporin A, prevents mitochondrial dysfunction during hypoxia
in rat hepatocytes
Life Sci 69:17-26
- Minami T, Matsumura S, Okuda-Ashitaka E, Shimamoto K, Sakimura K, Mishina M, Mori, H and Ito S(2001)
Characterization of the glutamatergic system for induction and maintenance of
allodynia.
Brain Res 895:178-185
- Minami T, Bakoshi S, Nakano H, Mine O, Muratani T, Mori H and Ito S(2001)
The effects of capsaicin cream on prostaglandin-induced allodynia.
Anesth Analg 93:419-423
- Minami T, Nakano H, Kobayashi T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S and Ito S(2001)
Characterization of EP receptor subtypes responsible for prostaglandin
E2-induced
pain responses by use of EP1 and EP3 receptor knockout mice.
Br J Pharmacol 133:438-444
- Inoue M, Takahashi S, Yamashina I, Kaibori M, Okumura T, Kamiyama
Y, Vichier-Guerre S, Cantacuzene D and Nakada H(2001)
High density O-glycosylation of the MUC2 tandem repeat unit by
N-acetylgalactosaminyltransferase-3 in colonic adenocarcinoma extracts.
Cancer Res 61:950-956
- Oyaizu H, Adachi Y, Okumura T, Okigaki M, Oyaizu N, Taketani S,
Ikebukuro K, Fukuhara S and Ikehara S(2001)
Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in human lung
adenocarcinoma cell line.
Oncol Rep 8:825-829
- Maruyama R, Kawata A, Ono S, Nishizawa M, Ito S and Inoue M(2001)
Effects of amino acids on the amidation of polyaromatic carboxylic acids by
Bacillus cereus.
Biosci Biotech Biochem 65:1761-1765
- Maruyama R, Nishizawa M, Itoi Y, Ito S and Inoue M(2001)
Isolation and expression of a Bacillus cereus gene encoding benzil reductase.
Biotech Bioeng 75:630-633
- Doi Y, Minami T, Nishizawa M, Mabuchi T, Mori H and Ito S(2001)
Central nociceptive role of prostacyclin (IP) receptor induced by peripheral inflammation.
Neuroreport 13:93-96
- Kato Y, Hamada Y, Nakai K, Kitagawa K, Ito S, Okumura T and Hioki K(2002)
Effect of epidermal growth factor on intestinal adaptation after allogeneic small bowel transplantation in rats.
Life Sci 70: 809-819
- Kaibori M, Inoue T, Oda M, Naka D, Kawaguchi T, Kitamura N,
Miyazawa K, Kwon A-H, Kamiyama Y and Okumura T (2002)
Exogenously administered HGF-activator augments liver regeneration through the
production of biologically active HGF.
Biochem Biophys Res Commun 290: 475-481
- Maruyama R, Nishizawa M, Itoi Y, Ito S and Inoue M(2002)
The enzymes with benzil reductase activity conserved from bacteria to mammals.
J Biotechnol 94: 157-169
- Okuda-Ashitaka E, Minami T and Ito S(2002)
Pain transmission regulated by novel neuropeptides nocistatin and
nociceptin/orphanin FQ.
J Biol Macromol 2: 3-10
- Tanikawa N, Ohmiya Y, Ohkubo H, Hashimoto K, Kangawa K, Kojima M, Ito S and Watanabe K(2002)
Identification and characterization of a novel type of membrane-associated
prostaglandin E synthase.
Biochem Biophys Res Commun 291:884-889
- Kitano M, Okumura T, Nishizawa M, Liew FY, Seki T, Inoue K and
Ito S(2002)
Altered response to inflammatory cytokines in energy metabolism in inducible
nitric oxide synthase knockout mice.
J Hepatol 36:759-765
Áí¡¡¡¡Àâ
- Æî¡¡ÉÒÌÀ¡¢°ËÆ£À¿Æó¡Ê2001¡Ë
ÄˤߤβÄÁºÀ.
À¸ÊªÊªÍý 41:15-19
- ³¤ËÙ¾»¼ù¡¢°æ¾åÃεס¢ÅÚ²°±Ñ¿Í¡¢²£°æÀµð¡¢ÜÞ¡¡²í·û¡¢¾å»³¡¡ÂÙÃË¡¢±ü¼Ãé˧¡Ê2001¡Ë
´Î¡¤ÎÄã»ÀÁǾ㳲¤ËÂФ¹¤ëFK506¤ÎÊݸî¸ú²Ì.
º£Æü¤Î°Ü¿¢ 14:61-66
- Ito S, Okuda-Ashitaka E and Minami T (2001)
Central and peripheral roles of prostaglandins in pain and their interactions
with novel neuropeptides nociceptin and nocistatin.
Neurosci Res 41: 299-332
- °ËÆ£À¿Æó¡¢¾¾Â¼¿¼£¡¢Æî¡¡ÉÒÌÀ¡Ê2002¡Ë
À¸²½³Ø¤ÎΩ¾ì¤«¤é¤ß¤¿ÄˤߤÎʬ»Òµ¡¹½¤È¼£ÎÅ
¥Ú¥¤¥ó¥¯¥ê¥Ë¥Ã¥¯ 23: 363-368
³Ø²ñȯɽ
- Ito S (2001)
Roles of prostaglandins in nociception.
7th International Congress on PAF and Lipid Mediators, Tokyo
- Mine O, Matsumura S, Minami T, Sakai M, Okuda K, Takahashi H, Oka S, Kojima H, Nagano T, Fukasaku N, Mori H and Ito S (2001)
Production of nitric oxide by prostaglandin E2 in NG 108-15 cells.
The 31st Annual Meeting of Society for Neuroscience, San Diego, U.S.A.
- Ito S, Yamada H, Nakano H, Kobayashi T, Sugimoto Y, ushikubi F, Ichikawa A, Narumiya S, Mori H and Minami T (2001)
Characterization of EP receptor subtypes responsible for prostaglandin
E2-induced pain responses by EP1 and EP3 knockout mice.
The 31st Annual Meeting
of Society for Neuroscience, San Diego, U.S.A.
- Muratani T, Minami T, Nakano H, Okuda-Ashitaka E, Maekawa M, Mori H and Ito S (2001)
Effect of JTC-801, a novel nociceptin (Noc/OFQ)
receptor antagonist, on pain responses in the formalin test.
The 31st Annual Meeting of Society for Neuroscience, San Diego, U.S.A.
- Minami T, Matsumura S, Okuda-Ashitaka E, Shimamoto K,
Imamura K, Mishina M, Mori H and Ito S (2001)
Characterization of the glutamatergic system for induction and maintenance
of PG-induced allodynia.
The 31st Annual Meeting of Society for Neuroscience, San Diego, U.S.A.
- Nakai K, Hamada Y, Kitagawa K, Kato Y and Okumura T
(2001)
Effect of epidermal growth factor on the induction of dipeptide
co-transporter after allogeneic small bowel transplantation.
VII International Small Bowel Transplantation Symposium, Stockholm,
Sweden.
- Kitagawa K, Hamada Y, Nakai K, Kato Y and Okumura T
(2001)
Comparison of one- and two-step procedures in a rat model of small bowel
transplantation.
VII International Small Bowel Transplantation Symposium, Stockholm,
Sweden.
- Tachibana S, Lee T-L, Ricos MG, Fung FMY, Zhang G, Chen
F-G, Chou N, Okuda-Ashitaka E, Ito S, Nishiuchi Y and Kimura T (2001)
Comparison of nocistatin levels in CSF among chronic acute, non-pain patients
and normal volunteers.
The 32nd International Narcotics Research Conference.
- °ËÆ£À¿Æó¡¢°²¹â·ÃÈþ»Ò (2001)
¥Î¥·¥¹¥¿¥Á¥ó¤È¥Î¥·¥»¥×¥Á¥ó¤Ë¤è¤ëÄ˳ÐÄ´Àᵡ¹½
Â裵²ó¿À·ÐÅÁãʪ¼Á¸¦µæ²ñ¡¢Åìµþ
- Watanabe K, Yamamoto-Suzuki T, Nishizawa M, Tsutsui
Y, Ishimura K and Ito S (2001)
Prostaglandin F synthase.
Âè74²óÆüËÜÀ¸²½³Ø²ñ¡¢µþÅÔ
- ³¤ËÙ¾»¼ù¡¢°æ¾åÃεס¢¾®ÅÄÆ»Éס¢ËÅçÌС¢ÃæÀ¾±Ñ¼ù¡¢´î¿¼ľ¼Â¡¢µÜß··ÃÆó¡¢ÜÞ²í·û¡¢¾å»³ÂÙÃË¡¢±ü¼Ãé˧ (2001)
³°°øÀHGF activator¤Ë¤è¤ë70%´ÎÉôʬÀÚ½ü¥é¥Ã¥È¤Î´ÎÆâHGF¤Î³èÀ²½
Âè74²óÆüËÜÀ¸²½³Ø²ñ¡¢µþÅÔ
- Tu Wei¡¢Ë̽йÀ¾Ï¡¢Î¤°æÁÔÊ¿¡¢ÃæÀ¾±Ñ¼ù¡¢ËÅçÌС¢³¤ËÙ¾»¼ù¡¢ÜÞ²í·û¡¢¾å»³ÂÙÃË¡¢±ü¼Ãé˧ (2001)
Êĺ¿À²«áդˤè¤ë°ì»À²½ÃâÁǤλºÀ¸Â¥¿Ê¤Ï´Îµ¡Ç½¾ã³²¤Ë´ØÍ¿¤¹¤ë
Âè74²óÆüËÜÀ¸²½³Ø²ñ¡¢µþÅÔ
- °ËÆ£À¿Æó¡¢¾¾Â¼¿¼£¡¢°²¹â·ÃÈþ»Ò¡¢ÅçËÜ·¼»Ò¡¢»°Éʾ»Èþ¡¢ÆîÉÒÌÀ (2001)
ÀÔ¿ñ¤ÎÄ˳ÐÅÁã¤Ë¤ª¤±¤ë¥°¥ë¥¿¥ß¥ó»À¤ÎÌò³ä
Âè74²óÆüËÜÀ¸²½³Ø²ñ¡¢µþÅÔ
- À¾ß·´´Íº¡¢´Ý»³Îå¼£¡¢»å°æÂÙ¡¢°æ¾åÀµÈþ¡¢°ËÆ£À¿Æó (2001)
ºÙ¶Ý¤«¤éÓ®ÆýÎà¤Þ¤ÇÊݸ¤µ¤ì¤Æ¤¤¤ë¥Ù¥ó¥¸¥ë´Ô¸µ¹ÚÁǤβòÀÏ
Âè74²óÆüËÜÀ¸²½³Ø²ñ¡¢µþÅÔ
- ÇÏÞ¼·½À¸¡¢¹¾¸ýľÈþ¡¢Î¢½ÐÎÉÇî¡¢ÉðÆ£À¿¡¢°ËÆ£À¿Æó (2001)
¿À·Ð°øÀáÖÄˤˤª¤±¤ë¥×¥í¥¹¥¿¥°¥é¥ó¥¸¥ó¤Î´ØÍ¿
Âè74²óÆüËÜÀ¸²½³Ø²ñ¡¢µþÅÔ
- °ËÆ£À¿Æó (2001)
¥Î¥Ã¥¯¥¢¥¦¥È¥Þ¥¦¥¹¤òÍѤ¤¤¿Ä˳ÐÈ¿±þ¤Î²òÀÏ
¡ÖÁÏÌôÌôÍý¥Õ¥©¡¼¥é¥à¡×Â裲£µ²óÃÌÏòñ, Åìµþ
- °ËÆ£À¿Æó (2001)
¿À·Ð°øÀáÖÄˤÎʬ»Òµ¡¹½
Â裳£µ²óÆüËÜ¥Ú¥¤¥ó¥¯¥ê¥Ë¥Ã¥¯³Ø²ñÂç²ñ¡¢´ôÉì
- °ËÆ£À¿Æó (2001)
»é¼Á¥á¥Ç¥£¥¨¡¼¥¿¡¼¤ÈÄˤ߼õÍÆ
Â裲£´²óÆüËÜ¿À·Ð²Ê³Ø¡¦Â裴£´²óÆüËÜ¿À·Ð²½³Ø¡¡¹çƱÂç²ñ¡¢µþÅÔ
- °ËÆ£À¿Æó (2001)
¥Î¥Ã¥¯¥¢¥¦¥È¥Þ¥¦¥¹¤òÍѤ¤¤¿ÄË¤ß¤Î¹ÔÆ°²òÀÏ
°äÅÁ»ÒƳÆþ¸¦µæ²ñ¡¢Åìµþ
- °ËÆ£À¿Æó (2001)
À¸Êª¿·µ¡Ç½¤ÈÁÏÌô¤ò¤á¤¶¤¹À¸ÂÎÆâʬ»Ò²Ê³Ø
³Ø½ÑÁÏÀ®Â裱²ó¥·¥ó¥Ý¥¸¥¦¥à
- Ãæ°æ¹¨¼£¡¢ßÀÅĵȧ¡¢²ÃÆ£ÂÙµ¬¡¢ËÌÀî¹îɧ¡¢°ËÆ£À¿Æó¡¢±ü¼Ãé˧¡¢ÆüÃֹɻÎϺ (2001)
¥é¥Ã¥È°Û·Ï¾®Ä²°Ü¿¢¤Ë¤ª¤±¤ëepidermal growth factor (EGF)
¤ÎÅü¤ª¤è¤Ó¥¸¥Ú¥×¥Á¥ÉÍ¢Á÷óÂΤ˴ؤ¹¤ë¸¡Æ¤
Âè16²óÀÅÌ®·ÐIJ³Ø²ñ¡¢²£ÉÍ
- Ãæ°æ¹¨¼£¡¢ßÀÅĵȧ¡¢²ÃÆ£ÂÙµ¬¡¢ËÌÀî¹îɧ¡¢°ËÆ£À¿Æó¡¢±ü¼Ãé˧¡¢ÆüÃֹɻÎϺ (2001)
¥é¥Ã¥È¾®Ä²°Ü¿¢¤Ë¤ª¤±¤ëEGF¤¬µÚ¤Ü¤¹°Ü¿¢Ä²´ÉÇ´Ëì¤ÎÅü¾Ã²½µÛ
¼ýÂ¥¿Ê¸ú²Ì¤Î¸¡Æ¤
Âè101²óÆüËܳ°²Ê³Ø²ñ¡¢ÀçÂæ
- Ãæ°æ¹¨¼£¡¢ßÀÅĵȧ¡¢²ÃÆ£ÂÙµ¬¡¢ËÌÀî¹îɧ¡¢°ËÆ£À¿Æó¡¢±ü¼Ãé˧¡¢ÆüÃֹɻÎϺ (2001)
¥é¥Ã¥È¾®Ä²°Ü¿¢¤Ë¤ª¤±¤ëEGF¤Î¸ú²Ì¡¦ÆóÅüÎàʬ²ò¹ÚÁǤÈNa+/¥°¥ë¥³¡¼¥¹Í¢Á÷ÂÎ
Âè38²ó¾®»ù³°²Ê³Ø²ñ¡¢Åìµþ
- ³¤ËÙ¾»¼ù¡¢°æ¾åÃεס¢¾®ÅÄÆ»Éס¢ÜÞ²í·û¡¢±ü¼Ãé˧¡¢¾å»³ÂÙÃË (2001)
´Î¡¤ÎÄã»ÀÁÇ¡¦ºÆ»ÀÁDz½¤Î˦¾ã³²¤ËÂФ¹¤ëFK506¤ÎÊݸî¸ú²Ì
Âè101²óÆüËܳ°²Ê³Ø²ñ¡¢ÀçÂæ
- ³¤ËÙ¾»¼ù¡¢ËÅçÌС¢ÃæÀ¾±Ñ¼ù¡¢µÜß··ÃÆó¡¢´î¿¼ľ¼Â¡¢ÜÞ²í·û¡¢¾å»³ÂÙÃË¡¢±ü¼Ãé˧ (2001)
³°°øÀHGF³èÀ²½°ø»Ò¤Ë¤è¤ë´ÎÉôʬÀÚ½ü¥é¥Ã¥È¤Î´ÎºÆÀ¸¤ÎÂ¥¿Ê
Âè8²ó´ÎºÙ˦¸¦µæ²ñ¡¢Åìµþ
- °æ¾åÃεס¢ÃæÀ¾±Ñ¼ù¡¢ËÅçÌС¢³¤ËÙ¾»¼ù¡¢À¾ß·´´Íº¡¢°ËÆ£À¿Æó¡¢±ü¼Ãé˧(2001)
Äã»ÀÁǤˤª¤±¤ë´ÎºÙ˦¤Î°ì»À²½ÃâÁǹçÀ®¹ÚÁÇȯ¸½Í¶Æ³¤ÎÍÞÀ©¤È¤½¤Îµ¡¹½
Âè48²óÆüËÜÀ¸²½³Ø²ñ¶áµ¦»ÙÉôÎã²ñ¡¢ÆàÎÉ
- Ãæ°æ¹¨¼£¡¢ßÀÅĵȧ¡¢ËÌÀî¹îɧ¡¢²ÃÆ£ÂÙµ¬¡¢ÇÏÅÂŰÌ顢ʡÅĽ¨ÌÀ¡¢°ËÆ£À¿Æó¡¢±ü¼Ãé˧¡¢ÆüÃֹɻÎϺ (2001)
¥é¥Ã¥È¾®Ä²°Ü¿¢¤Ë¤ª¤±¤ëEGF¤Î¸ú²Ì¡¦PepT1ȯ¸½¤ÈÆóÅüÎàʬ²ò¹ÚÁÇȯ¸½¤Ë¤Ä¤¤¤Æ
Â裴²ó¶áµ¦ÉÂÂÖ¸¦µæ²ñ¡¢Âçºå
- À¾ß·´´Íº¡¢´Ý»³Îå¼£¡¢»å°æÂÙ¡¢°æ¾åÀµÈþ¡¢°ËÆ£À¿Æó (2001)
¥»¥ì¥¦¥¹¶Ý¤Î¥Ù¥ó¥¸¥ë´Ô¸µ¹ÚÁÇ¡¢¹ÚÊì¤ÎYIR036CÃÁÇò¼Á¤È¥¹¥Ê¥Í¥º¥ß¤Î
¥»¥Ô¥¢¥×¥Æ¥ê¥ó´Ô¸µ¹ÚÁǤÎÈæ³Ó
Â裲£´²óÆüËÜʬ»ÒÀ¸Êª³Ø²ñ¡¢²£ÉÍ
- °²¹â·ÃÈþ»Ò¡¢ÆîÉÒÌÀ¡¢°ËÆ£À¿Æó (2001)
ÄˤߤÎʬ»Òµ¡¹½
ÆüËÜÀ¸Êª¹âʬ»Ò³Ø²ñ2001ǯÅÙÂç²ñ¡¢µþÅÔ
Ãø¡¡¡¡½ñ
- °ËÆ£À¿Æó¡¢°²¹â·ÃÈþ»Ò¡¢Æî¡¡ÉÒÌÀ¡Ê2001¡Ë
Äˤ߸¦µæ¤ÎºÇÁ°Àþ¡¡¥Î¥·¥»¥×¥Á¥ó´ØÏ¢¡¡¥Î¥·¥¹¥¿¥Á¥ó¤ÎÄÃÄ˺îÍÑ
¥ª¥Ô¥ª¥¤¥É¼£ÎÅ
²ÝÂê¤È¿·Ä¬Î®¡Ê¥ß¥¯¥¹¡Ë260-267ÊÇ.
- °ËÆ£À¿Æó¡¢°²¹â·ÃÈþ»Ò¡Ê2001¡Ë
¥Î¥·¥¹¥¿¥Á¥ó¤È¥Î¥·¥»¥×¥Á¥ó¤Ë¤è¤ëÄ˳ÐÄ´Àᵡ¹½
¿À·Ð¥Ú¥×¥¿¥¤¥É¡¡ºÇ¿·¤ÎÏÃÂê¡¡
Â裵²ó¿À·ÐÅÁãʪ¼Á¸¦µæ²ñµÏ¿½¸¡Êº´Æ£¸øÆ»¡¡ÊÔ½¸¡Ë2-9ÊÇ,¡¡¥¨¥¯¥»¥×¥¿¥á¥Ç¥£¥«
- Æî¡¡ÉÒÌÀ¡¢¿¹¡¡½¨Ëû¡¢°ËÆ£À¿Æó¡Ê2001¡Ë
ÀÔ¿ñ¤Ë¤ª¤±¤ëÄˤߤÎÅÁ㵡¹½
Î×Ëã¡¡Î×»þÁý´©¹æ299-310ÊÇ,¡Ê¿¿¶½¸ò°×¡Ë
Ê¿À®13ǯ¶ÈÀÓÌÜÏ¿°ìÍ÷¤ËÌá¤ë